Europe Asthma Treatment Market (By Treatment: Long-Term Control Medications, Quick-Relief Medications; By Route of Administration: Injectable, Oral, Inhaled; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies) Industry Size, Share, Growth, Trends 2025 to 2034
The Europe asthma treatment market exceeded USD 7.64 billion in 2024 and is forecast to reach USD 9.42 billion by 2034, expanding at a modest 2.12% CAGR, supported by rising asthma prevalence and advancements in inhalation therapies.
| Reports Attributes | Statistics |
| Market Size in 2024 | USD 45.35 Million |
| Market Size in 2025 | USD 47.3 Million |
| Market Size in 2031 | USD 60.89 Million |
| Market Size by 2034 | USD 69.09 Million |
| CAGR 2025 to 2034 | 4.3% |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
Demand in Europe is driven by both persistent prevalence and evolving treatment paradigms. Epidemiological studies show that asthma prevalence among adults in multiple European countries ranges around 6.7 % (95% CI: 6.5-6.9 %) in the five-country EU study. These levels highlight large patient populations requiring ongoing therapy. The shift toward biologic therapies for severe asthma adds new growth tails: a 2024 European Respiratory Journal article noted approved biologics for severe asthma are growing in use across Europe.
Another driver is the increased emphasis on digital health solutions and personalized medicine. Advanced inhaler devices, smart monitoring of medication adherence, and digital platforms supporting patient self-management are gaining traction, particularly in Western Europe. As public health systems prioritize reducing hospital admissions and exacerbations, reimbursement and clinical guidelines increasingly favour such technologies. This broader push for optimized asthma care supports growth across controller, rescue, and advanced therapy segments.
Despite robust demand, the market faces structural and access-related barriers. One key issue is heterogeneous access to advanced therapies among countries. A 2024 study revealed significant variation in biologic use across Europe, with access, reimbursement, and provider practices differing markedly. These inconsistencies limit penetration of newer high-cost therapies, especially in mid- and Eastern European markets.
Another barrier is the persistent gap in inhaler adherence and asthma control. Studies indicate that even in Europe, many patients do not use inhalers correctly, undermining outcomes and increasing treatment burden. Training, behavioural support, and device usability remain important hurdles. Moreover, the high cost of biologics, combined with stringent regulatory requirements and long development cycles, slows the introduction and uptake of novel treatments in certain markets.
Western Europe holds the largest share of the regional asthma treatment market, supported by high healthcare spending, established respiratory care infrastructure, and strong patient access. Countries like Germany and France lead in therapy uptake, digital tool adoption, and guideline implementation. Central and Northern Europe also show solid uptake of biologics and smart inhaler technology. For example, Germany’s well-funded respiratory networks and France’s national asthma programs drive demand.
Eastern and Southern Europe present faster growth potential but start from lower bases. These regions are catching up as healthcare systems upgrade, reimbursement expands, and awareness rises. Air-pollution-affected urban areas in Southern Europe also signal higher unmet demand. Across Europe, collaborations between academic research centres (such as the GA²LEN network) and industry support innovation in asthma treatment and personalized care.
Germany Europe Asthma Treatment Market
Germany’s asthma treatment market is among the most advanced in Europe. Strong primary care and specialist networks, widespread use of combination inhalers and biologics, and rapid adoption of digital adherence programs characterise the market. National data show high usage of respiratory care devices and digital health solutions. While costs remain high for newer therapies, reimbursement is relatively strong, enabling broader patient access. Training of healthcare professionals in inhaler technique and patient education is well established, supporting market development.
France Europe Asthma Treatment Market
The France market is similarly mature and benefits from a national respiratory disease strategy, high patient awareness, and a strong specialist care infrastructure. A 2021 French study on severe asthma highlighted gaps in phenotyping, as well as the rising adoption of biologic therapies. Public programmes promoting self-management, air-quality initiatives, and national reimbursement mechanisms further support uptake of advanced asthma treatments. France is emphasising digital inhaler monitoring and remote patient management to bridge the gap between standard inhaler therapy and specialty biologic care.
| Regions | Shares (%) |
| Long-Term Control Medications | 72% |
| Quick-Relief Medications | 28% |
| Segments | Shares (%) |
| Injectable | 10% |
| Oral | 25% |
| Inhaled | 65% |
| Segments | Shares (%) |
| Hospital Pharmacies | 30% |
| Retail Pharmacies & Drug Stores | 55% |
| Online Pharmacies | 15% |
Published by Kesiya Chacko
